Iron and Infection

References

• Fondu P, Cantinieaux B. Infections and iron overload. Acta Clin Belg. 1986; 41: 1–9.
   Google Scholar
• Weinberg ED. Iron and infection. Microbiol Rev. 1978; 42:45–66.
   Google Scholar
• Kochan I. The role of iron in bacterial infections, with special consideration of host-tubercle bacillus interaction. Curr Top Microbiol Immunol. 1973; 60:1–30.
   Google Scholar
• Brock J. Lactoferrin: a multifunctional immunoregulatory protein? Immunol Today. 1995; 16: 4179.
   Google Scholar
• Bellamy W, Takase M, Yamauachi K, Wakabayashi H, Kawase K. Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim BiophysActa. 1992; 1121: 130–6.
   Google Scholar
• Bullen JJ, Spalding PB, Ward CG, Gutteridge JMC. Hemochromatosis, iron, and septicemia causcd by Vibrio vulnificus. Arch Intern Med. 1991; 151: 1606–09.
   Google Scholar
• Speeleveld E, Muyldermans L, Van Den Bruel A, Dhondt E, Gordts B, Van Landuyt HW. Prosthetic valve endocarditis due to Listeria monocytogenes. Acta Clin Belg. 1994: 49; 95–8.
   Google Scholar
• Artis WA, Fountain JA, Dclchcz HK, Jones HE. A mechanism of suceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron bioavailability. Diabetes. 1982; 31: 1109–14.
   Google Scholar
• Gupta KL, Radotra BP, Sakhuja V, Banarjee AK, Chugh KS. Mucormycosis in patients with renal failure. Renal Failure. 1990; 11:195–9.
   Google Scholar
• Lewis LL, Hawins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonic aciduria. Pediatr Infect Dis J. 1990; 9: 851–4.
   Google Scholar
• Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80: 1639–47.
   Google Scholar
• Weiss G, Wachter H, Fuchs D. Linkage of cellmediated immunity to iron metabolism. Immunol Today. 1995; 16: 495–9.
   Google Scholar
• Byrd TF, Horwitz MA. Interfcron-gamma activated human monocytes downregulate transferrin receptors and inhibit the intracellular inulplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest. 1988; 83: 1457–65.
   Google Scholar
• Weinberg ED. Iron depiction: a defense against intracellular infection and neoplasia. Life Sciences. 1992; 50: 1289–97.
   Google Scholar
• Albina JE. On the expression of nitric oxide synthase in human macrophages. Why no NO? J Leukoc Biol. 1998; 58: 643–9.
   Google Scholar
• Weinberg ED. Acquisition of iron and other nutrients in vivo. In: Roth JA et al., eds. Virulence mechanisms of bacterial pathogens. Washington DC: American society for microbiology. 1995; 8195.
   Google Scholar
• Crichton RR. Inorganic biochemistry of iron metabolism. Ellis Horwood, ed. New York: Ellis Horwood series in inorganic chemistry. 1991.
   Google Scholar
• Drechsel H, Metzger J, Frcund S, Jung G, Boelaert JR, Winkelmann G. Rhizoferrin-a novel siderophore from the fungus Rhizopus microsporus var. rhizopodiformis. Biol Metals. 1991; 4: 238–43.
   Google Scholar
• Brittenham GM. Development of iron-chelating agents for clinical use. Blood. 1992; 80: 569–74.
   Google Scholar
• Robins-Browne RM, Prpic JK. Desferoxamine and systemic yersiniosis. Lancet. 1983; 2: 1372.
   Google Scholar
• Boelaert JR et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis. 1987; 156: 384–6.
   Google Scholar
• Dc Brouwer E, Van Landuyt HW, Gordts B, Boelaert JR. In vitro acquisition of iron from the irondesferrioxamine complex by Aeromonas hydrophila. Clin Microbiol Infect. 1996, in press.
   Google Scholar
• Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991; 18: 660–7.
   Google Scholar
• Boelaert JR, de Locht M, Schneider Y-J. The effect of deferoxamine on different zygomycetes. J Infect Dis. 1994; 169:231–2.
   Google Scholar
• Van Cutsem J, Boelaert JR. Effects of deferoxamine, fcroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 1989; 36: 1061–68.
   Google Scholar
• Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine is a siderophoremediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91: 1979–86.
   Google Scholar
• Van den Saffele JK, Boelaert JR. Zygomycosis in HIV-positive patients: a review of the literature. Mycoses. 1996, in press.
   Google Scholar
• Vcrpooten GA, D’Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferoxamine in haemodialysis patients. Nephrol Dial Transplant. 1992; 7: 931–8.
   Google Scholar
• Boelaert JR, Van Cutsem J, dc Locht M, Schneider Y-J, Crichton RR. Deferoxamine augments growth and pathogenicity at Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Intern. 1994; 45:667–71.
   Google Scholar
• Gordeuk VR et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med. 1992; 326: 95–100.
   Google Scholar
• Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant. 1990; 5: 130–4.
   Google Scholar
• Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. Nephron. 1993; 64: 95–100.
   Google Scholar
• Gordeuk VR, Thuma P, Brittenham G et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med. 1992; 327: 1473–77.
   Google Scholar
• Gordeuk VR et al. Transferrin saturation and recovery from coma in cerebral malaria. Blood. 1995; 85: 3297–301.
   Google Scholar
• Raghu B, Raghupati S, Venkatesan P. Effect of iron on the growth and siderophore production of mycobacteria. Biochem Molec Biol Intern. 1993; 31:341–8.
   Google Scholar
• Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. Br Med J. 1978; 2:1113–15.
   Google Scholar
• Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan’s 1929 thesis revisited. Blood. 1996; 87: 3470–76.
   Google Scholar
• Boelaert JR. Weinberg GA. Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis. 1996; 5: 36–46.
   Google Scholar
• Boelaert JR, Piette J, Weinberg GA, Sappey C, Weinberg ED. Iron and oxidative stress as a mechanism for the enhanced production of human immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. J Irtfect Dis. 1996; 173:1045–46.
   Google Scholar
• A. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-kB and HIV-1 activation due to oxidative stress. AIDS Res Hum Retroviruses. 1995; U: 1049–61.
   Google Scholar
• Costagliola D, de Montalembert M, Lcfrfere J-J et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol 1994; 87: 849–52.
   Google Scholar
• Van Asbeck BS, Verburgh HA, Van Oost BA, Marx JJM, Imhof HW, Verhoef J. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J. 1982; 284: 542–4.
   Google Scholar
• Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol. 1992; 80: 235–41.
   Google Scholar
• De Sousa M. Immune cell functions in iron overload. Clin Exp Immunol. 1989; 75:1–6.
   Google Scholar
• Mosmann TR, Coffmann RL. TH1 and TH2 cells: different patterns of lymphokine secretions lead to j different functional properties. Ann Rev Immunol. 1989; 7: 145–73.
   Google Scholar
• Clerici M, Shearer GM. A TH 1 =>TH2 switch is a) critical step in the etiology of HIV infection. Immunol Today. 1993, 14: 107–11.
   Google Scholar
• Gougeon ML, Olivier S, Garcia et al. Mise en dvidence d’un processus d’engagemcnt vers la mort cellulaire par apoptose dans les lymphocytes de patients infectds par le VIH. C R Acad Sci Paris, SerllISc Vie. 1991; 312: 529–40.
   Google Scholar
• Clerici M, Sarin A, Coffman RL et al. Type 1/type 2 cytokine modulation of T cell programmed cell death as a model for HIV pathogenesis. Proc Natl Acad Sci USA. 1994; 91: 11811–75.
   Google Scholar
• Weinberg ED, Weinberg GA. The role of iron in infection. Curr Opin Infect Dis. 1993; 8: 164–9.
   Google Scholar
• Boelaert JR, de Locht M, Van Cutsem J. Desferrioxamine and microorganisms. Studies on in vitro growth and on experimental infections. A review. Rev Med Microbiol. 1993; 4:171–5. I
   Google Scholar
• Cinatl J Jr, Cinatl J, Rabenau H, GUmbel HO, Kornhuber B, Doerr HW. In vitro inhibition of human cytomegalovirus replication by desferrioxamine. Antiviral Res. 1994; 25:73–7.
   Google Scholar
• Weinberg GA. Iron chelators as novel therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother. 1994; 38:997–1003.
   Google Scholar
• Newman SL, Gootee L, Brunner G, Deepe GS Jr. > Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest. 1994; 93:1422–29.
   Google Scholar
• Sperber K et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Therap. 1995; 17:622–36.
   Google Scholar
• Rubin RB, Barton AL, Banner BF, Bonkovsky HL. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis. 1995; 13:223–38.
   Google Scholar
• Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-alpha (Abstract). Hepatology. 1993; 18: 373.
   Google Scholar
• Hayashi H et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron. Am J Gastroenterol. 1984; 89: 986–8.
   Google Scholar